Comment from Krajewski Diane

I am writing as both a registered nurse and a patient to express my strong support for preserving access to compounded peptide therapies when they are prescribed and monitored by qualified healthcare providers. Peptides have completely changed my life. Under the care of my healthcare provider, I am currently using five different peptides, and I can honestly say I have never felt better. Since beginning treatment, I have lost 48 pounds. One of the biggest changes has been that the constant “food noise” that consumed my thoughts for years is now almost nonexistent. That freedom alone has been life-changing. Beyond the weight loss, my laboratory values have improved, my energy has increased dramatically, and my overall quality of life has never been better. I am more active, healthier, and able to fully enjoy my life in ways I hadn’t experienced in years. As a registered nurse, I also understand the importance of preventive healthcare. Too often, our healthcare system waits until people develop chronic disease before intervening. Peptide therapies have allowed me to be proactive instead of reactive. They have helped me improve my health before more serious complications could develop, and I believe patients deserve access to safe, individualized treatment options that support prevention and long-term wellness. Every patient is different. Not everyone responds the same way to medications, and not everyone has access to commercially available products because of cost, availability, allergies, dosing needs, or other individual circumstances. Compounded medications provide an essential option that allows healthcare providers to tailor treatment to the specific needs of each patient. Restricting access to compounded peptides will not eliminate the need for these therapies. It will simply push many patients toward unregulated gray-market products that lack the quality standards, testing, and medical oversight provided by licensed compounding pharmacies. That outcome would put patients at far greater risk. Patients and their healthcare providers should have the freedom to make informed, individualized decisions about their care. I respectfully urge the FDA to preserve access to compounded peptide therapies so patients can continue receiving safe, medically supervised, personalized treatment. Thank you for considering my comments and for recognizing the importance of patient choice, individualized medicine, and preventive healthcare.